| 宗大同,赵旭东,韩正祥,李 雷,刘 阳.血清LAG-3联合ANXA3水平与中晚期肝细胞癌患者仑伐替尼联合TACE治疗疗效的关系研究[J].现代生物医学进展英文版,2024,(19):3792-3794. |
| 血清LAG-3联合ANXA3水平与中晚期肝细胞癌患者仑伐替尼联合TACE治疗疗效的关系研究 |
| Study on the Relationship between Serum LAG-3 Combined with ANXA3 Levels and the Efficacy of Lenvatinib Combined with TACE in Patients with Intermediate and Advanced Hepatocellular Carcinoma |
| Received:June 05, 2024 Revised:June 30, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.19.051 |
| 中文关键词: 肝细胞癌 中晚期 淋巴细胞激活基因-3 膜联蛋白A3 仑伐替尼 经动脉化疗栓塞 疗效 |
| 英文关键词: Hepatocellular carcinoma Intermediate and advanced Lymphocyte-activated gene-3 Annexin A3 Lenvatinib Transcatheter arterial chemoembolization Efficacy |
| 基金项目:江苏省卫健委老年健康科研项目（LK2021015） |
|
| Hits: 11 |
| Download times: 6 |
| 中文摘要: |
| 摘要 目的：探讨血清淋巴细胞激活基因-3（LAG-3）联合膜联蛋白A3（ANXA3）与中晚期肝细胞癌（HCC）患者仑伐替尼联合经动脉化疗栓塞（TACE）治疗疗效的关系。方法：选取147例中晚期HCC患者，根据仑伐替尼联合TACE治疗后是否缓解分为缓解组与未缓解组。多因素Logistic回归模型分析中晚期HCC患者经仑伐替尼联合TACE治疗后未缓解的影响因素。结果：147例中晚期HCC患者经仑伐替尼联合TACE治疗后客观缓解率为36.05%，未缓解率为63.95%。未缓解组Child-Pugh分级B级比例、AFP≥400 μg/L比例、低分化比例、巴塞罗那肝癌分期（BCLC）C期、血管侵犯比例和血清LAG-3、ANXA3水平高于缓解组（P＜0.05）。Child-Pugh分级B级、低分化、BCLC分期C期、血管侵犯和LAG-3、ANXA3水平升高为中晚期HCC患者仑伐替尼联合TACE治疗后未缓解的独立危险因素（P＜0.05）。结论：血清LAG-3、ANXA3水平升高与中晚期HCC患者治疗后未缓解相关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between serum lymphocyte-activated gene-3 (LAG-3) combined with annexin A3 (ANXA3) and the efficacy of lenvatinib combined with transcatheter arterial chemoembolization (TACE) in patients with intermediate and advanced hepatocellular carcinoma (HCC). Methods: 147 patients with intermediate and advanced HCC were selected, and they were divided into remission group and non-remission group base on whether the combination of lenvatinib and TACE treatment whether to remission.The influencing factors of non-remission after treatment with lenvatinib combined with TACE in patients with intermediate and advanced HCC were analyzed by multifactorial logistic regression model. Results: The objective remission rate of 147 patients with intermediate to advanced HCC treated with lenvatinib in combination with TACE was 36.05%, and the non-remission rate was 63.95%. The proportion of Child-Pugh grade B, the proportion of AFP≥400 μg/L, the proportion of poor differentiation, Barcelona liver cancer staging (BCLC) stage C, the proportion of vascular invasion and the levels of serum LAG-3 and ANXA3 in non-remission group were higher than those in remission group(P<0.05). Child-Pugh grade B, poor differentiation, BCLC stage C, vascular invasion and elevated levels of LAG-3 and ANXA3 were independent risk factors for non-remission after lenvatinib combined with TACE in patients with intermediate and advanced HCC(P<0.05). Conclusion: Elevated serum LAG-3 and ANXA3 levels are associated with non-remission after treatment in patients with intermediate- and advanced-stage HCC. |
|
View Full Text
View/Add Comment Download reader |
| Close |
